Charles E. Barr, MD, MPH, Appointed Chief Science Officer of BBCIC
Alexandria, Va. Dec. 6 2017 – The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) is pleased to announce that Charles Barr, M.D., MPH, has been appointed Chief Science Officer (CSO). The BBCIC was convened by the Academy of Managed Care Pharmacy in 2015 to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
Dr. Barr’s extensive research experience crosses industry, academia and medicine. His prior leadership roles have centered on both clinical trial and observational research projects, and have included the use of large patient registries and real world data.
“BBCIC is honored to have someone of the caliber of Charlie to serve as our CSO,” said Bernadette Eichelberger, Program Director of BBCIC. “His deep knowledge and experience with real-world outcomes research makes him the ideal leader to advance BBCIC’s scientific and research mission.”
Before joining the BBCIC, Dr. Barr was Group Medical Director and Head of Strategy & External Relationships in U.S. Medical Affairs, Evidence for Access at Genentech, Inc. He also has held leadership positions at Pfizer Inc. and Pharmacia in Global and US Medical Affairs, U.S. Outcomes Research, Managed Care and Disease Management.
Prior to working in industry, Dr. Barr worked in academia for 15 years doing clinical teaching and research, implementation of electronic medical records, development and implementation of clinical guidelines, and clinical quality improvement. He has extensive experience in management of clinical trial repositories, large claims databases, outcomes research and patient registries. The driving passion of his career has been to advance the frontiers of knowledge, leveraging science and technology to empower patients, physicians and policy makers with the best research and data to inform decisions and achieve the best outcomes.
In addition, Dr. Barr participated in the original design and development of the National Library of Medicine’s Unified Medical Language System (UMLS) project, served on an advisory committee to NCQA on HEDIS audits and was on the planning committee for the Observational Medical Outcomes Partnership (OMOP). He was a consultant to the Society for Critical Care Medicine, winning the President’s Award for support of the Project IMPACT database of critical care patients.
He received his M.D. and Master of Public Health from Loma Linda University and completed post-doctoral studies in biomedical computing, biostatistics, and health policy and management at Harvard University School of Public Health.
The BBCIC is the only multi-stakeholder research network dedicated to monitoring biosimilars, and draws on large sets of de-identified medical and pharmacy data (100 million lives). Managed care and integrated delivery organizations have devoted significant resources to develop an infrastructure that makes possible active surveillance of biosimilars and novel in distributed research networks. The BBCIC marshals these resources for the important public health benefit inherit in monitoring biosimilar safety and effectiveness, using ongoing sequential analyses to compare biosimilars to their innovator product. Visit www.bbcic.org.